Cargando…
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
Rare or orphan diseases often are inherited and overwhelmingly affect children. Many of these diseases have no treatments, are incurable, and have a devastating impact on patients and their families. Regulatory standards for drug approval for rare diseases must ensure that patients receive safe and...
Autores principales: | Mulberg, Andrew E., Bucci-Rechtweg, Christina, Giuliano, Joseph, Jacoby, David, Johnson, Franklin K., Liu, Qing, Marsden, Deborah, McGoohan, Scott, Nelson, Robert, Patel, Nita, Romero, Klaus, Sinha, Vikram, Sitaraman, Sheela, Spaltro, John, Kessler, Vivian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368795/ https://www.ncbi.nlm.nih.gov/pubmed/30736861 http://dx.doi.org/10.1186/s13023-019-1017-5 |
Ejemplares similares
-
Sharing is caring: a call for a new era of rare disease research and development
por: Denton, Nathan, et al.
Publicado: (2022) -
Data silos are undermining drug development and failing rare disease patients
por: Denton, Nathan, et al.
Publicado: (2021) -
Can Interventional Cardiologists Help Deliver the UK Mechanical Thrombectomy Interventional Programme for Patients with Acute Ischaemic Stroke? A Discussion Paper from the British Cardiovascular Interventional Society Stroke Thrombectomy Focus Group
por: Routledge, Helen, et al.
Publicado: (2022) -
Together4RD position statement on collaboration between European reference networks and industry
por: Hedley, Victoria, et al.
Publicado: (2023) -
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
por: Annemans, Lieven, et al.
Publicado: (2017)